BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases, has announced the pricing of US$500 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. In connection with the offering, the company granted the initial purchasers an option to purchase up to an additional US$75 million aggregate principal amount of notes. The sale of the notes is expected to close on February 28, 2025, subject to customary closing conditions.
Latham & Watkins LLP represents the initial purchasers in the offering with a corporate team led by partners Greg Rodgers and Shayne Kennedy, with associates Ryan Gold, Greg Van Buiten, Andrew Bentz, and Steve Hess. Advice was also provided on tax matters by partners Elena Romanova, Aaron Bernstein, and Kirt Switzer.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
